Damora Posts $32M Q3 Loss as R&D Spending Jumps; Cash Runs to 2H 2029
DMRA has more than doubled off its 52-week low of $4.95.
Summary
Damora's Q3 net loss widened to $32.0 million from $3.1 million a year earlier as R&D jumped to $25.5 million from $1.4 million and G&A rose to $11.4 million from $1.7 million — the company is now spending like a clinical-stage biotech rather than a shell. The balance sheet is the story: $528.5 million in cash and securities as of September 30, with management guiding that funds operations into the second half of 2029, so there is no near-term financing overhang despite the burn. Operationally, the FDA cleared the DMR-001 IND and CLARITY-101 Phase 1/1b enrollment is running at multiple sites, with two proof-of-concept readouts targeted from mid-2027; two DMR-001 abstracts were accepted for ASH in December, including preclinical data claiming an average 95-fold potency edge over a reference antibody across 10 non-Type 1 CALR mutations. The company also signed an exclusive worldwide license with Paragon Therapeutics covering DMR-001 and DMR-002. Next hard catalysts: ASH data in December and the first DMR-002 regulatory submission in Q4 2026.
At the time of this announcement, DMRA was trading at $22.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.95 to $38.33. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.